The introduction of ABL1 tyrosine kinase inhibitors (TKIs) has provided a favorable life expectancy for patients with chronic myeloid leukemia (CML-CP) similar to that of the general populations [1]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.